Cointime

Sio Gene Therapies

company

About

Sio Gene Therapies is a clinical-stage biopharmaceutical company.

  • 101 - 250

Highlights

Total Funding Amount
$55M
Funding Rounds
1
Investors
1

Details

Last Funding Type
Post-IPO Debt
Last Funding Money Raised
$55M
Industries
Biopharma,Biotechnology,Neuroscience,Therapeutics
Founded date
Jan 1, 2014
Number Of Employee
101 - 250
Operating Status
Active

Sio Gene Therapies, formerly known as Axovant, is a clinical-stage company with a singular focus on pushing the boundaries of gene therapy to develop treatments for debilitating neurodegenerative diseases, including GM1 gangliosidosis, Tay-Sachs/Sandhoff disease, and Parkinson’s disease. Sio is leveraging its foundational scientific expertise built on decades of research, extensive collaborations with leading gene therapy institutes, and a flexible vector platform to liberate patients with debilitating diseases through the transformational power of gene therapies.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$55M
Sio Gene Therapies has raised a total of $55M in funding over 2 rounds. Their latest funding was raised on Feb 3, 2017 from a Post-IPO Debt round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Feb 3, 2017 Post-IPO Debt $55M 1 — — Detail

Investors

Number of Lead Investors
Number of Investors
—
1
Sio Gene Therapies is funded by 1 investors. Hercules Capital are the most recent investors.
Investor Name Lead Investor Funding Round
Hercules Capital — Post-IPO Debt
Cointime
Content
Company